BridgeBio Pharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $502.1 | $221.9 | $9.3 | $77.6 | $69.7 |
| Operating income | -$523.4 | -$593.0 | -$607.4 | -$512.2 | -$576.6 |
| Net income | -$732.9 | -$543.3 | -$653.3 | -$484.7 | -$586.5 |
| Cash Flow Statement | |||||
| Free cash flow | -$447.0 | -$521.7 | -$529.0 | -$424.3 | -$511.2 |
| Share repurchases | $48.3 | $0.0 | $0.0 | $0.0 | $200.0 |
Shares outstanding 195.5M · Free float 74.4%
Annual filing data through FY ended December 31, 2025; float as of September 12, 2026.